MX341536B - Epitopo y anticuerpos beta amiloide de oligomero especifico. - Google Patents

Epitopo y anticuerpos beta amiloide de oligomero especifico.

Info

Publication number
MX341536B
MX341536B MX2012010175A MX2012010175A MX341536B MX 341536 B MX341536 B MX 341536B MX 2012010175 A MX2012010175 A MX 2012010175A MX 2012010175 A MX2012010175 A MX 2012010175A MX 341536 B MX341536 B MX 341536B
Authority
MX
Mexico
Prior art keywords
epitope
amino acid
antibody
snk
oligomer
Prior art date
Application number
MX2012010175A
Other languages
English (en)
Other versions
MX2012010175A (es
Inventor
R Cashman Neil
Original Assignee
The Univ Of British Columbia *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44541581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341536(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Univ Of British Columbia * filed Critical The Univ Of British Columbia *
Publication of MX2012010175A publication Critical patent/MX2012010175A/es
Publication of MX341536B publication Critical patent/MX341536B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Abstract

La presente invención se refiere a un epítopo peptídico restringido novedoso derivado de Aß, en donde el epítopo comprende la secuencia de aminoácido SNK, composiciones de anticuerpo relacionadas y métodos de uso. Se describe un anticuerpo aislado que específicamente se une a un péptido cíclico que comprende el epítopo conformacional, el cual comprende la secuencia de aminoácido SNK y que corresponde corresponde a una región de nudillo que puede acceder al anticuerpo, de solvente expuesto de Aß oligomérico. También se describe un péptido antigénico que comprende un epítopo que tiene una configuración cíclica restringida, que comprende la secuencia de aminoácido SNK y que corresponde a una región de nudillo que puede acceder al anticuerpo, de solvente expuesto de Aß oligomérico. También se describen métodos para tratar, evitar y diagnosticar la enfermedad de Alzheimer.
MX2012010175A 2010-03-03 2011-03-03 Epitopo y anticuerpos beta amiloide de oligomero especifico. MX341536B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31016710P 2010-03-03 2010-03-03
PCT/CA2011/000238 WO2011106885A1 (en) 2010-03-03 2011-03-03 Oligomer-specific amyloid beta epitope and antibodies

Publications (2)

Publication Number Publication Date
MX2012010175A MX2012010175A (es) 2012-11-23
MX341536B true MX341536B (es) 2016-08-24

Family

ID=44541581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010175A MX341536B (es) 2010-03-03 2011-03-03 Epitopo y anticuerpos beta amiloide de oligomero especifico.

Country Status (17)

Country Link
US (3) US9216217B2 (es)
EP (2) EP3056510B1 (es)
JP (2) JP6190113B2 (es)
KR (1) KR101831459B1 (es)
CN (1) CN102858796B (es)
AU (1) AU2011223456A1 (es)
BR (1) BR112012022229A2 (es)
CA (1) CA2791538C (es)
CL (1) CL2012002438A1 (es)
CO (1) CO6640211A2 (es)
IL (1) IL221695B (es)
MX (1) MX341536B (es)
NZ (1) NZ602548A (es)
RU (1) RU2644335C2 (es)
SG (1) SG183854A1 (es)
WO (1) WO2011106885A1 (es)
ZA (1) ZA201206916B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071267A1 (en) * 2011-11-10 2013-05-16 Cangene U.S., Incorporated Compositions and methods for treating alzheimer's disease
SG183854A1 (en) 2010-03-03 2012-10-30 Univ British Columbia Oligomer-specific amyloid beta epitope and antibodies
TWI571207B (zh) 2011-06-26 2017-02-21 安麗托克斯公司 用於條件化動物飼料之寒冷天氣調配物
ES2754308T3 (es) * 2012-04-05 2020-04-16 Forschungszentrum Juelich Gmbh Polímeros que contienen péptidos D multivalentes que se unen a beta-amiloide y su uso
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
CA3004498A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
CN108350052A (zh) * 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
EP3374382A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED SELECTIVE CONFORMATIONAL ANTIBODIES
WO2017079836A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Systems and methods for predicting misfolded protein epitopes by collective coordinate biasing
CA3004482A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
AU2019318195A1 (en) * 2018-08-09 2021-03-04 F. Hoffmann-La Roche Ag Determination of parkinson's disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
CA2250075C (en) * 1996-03-29 2008-06-10 The Trustees Of Boston University Methods for diagnosing and treating alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US6686443B1 (en) 2000-05-26 2004-02-03 The Regents Of The University Of California Chemical reagents for formation of disulfide bonds in peptides
DE04759123T1 (de) 2003-04-07 2005-08-18 Novetide Ltd. Verfahren zur herstellung cyclischer peptide
EP1484336A1 (en) 2003-06-02 2004-12-08 Pevion Biotech Ltd. Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines
US20080044356A1 (en) * 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
IL169622A0 (en) 2005-07-11 2007-07-04 Yeda Res & Dev Methods of screening modulators of interleukin-32 (il-32)modulators of il-32 identified by said methods and their use
WO2007011639A2 (en) * 2005-07-13 2007-01-25 Coimmune Inc. Catalytic immunoglobulins
CA2644952A1 (en) 2006-03-01 2007-09-13 The University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CN101622276B (zh) 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
NZ590324A (en) * 2008-07-01 2012-08-31 Nederlanden Staat Vaccine against amyloid folding intermediate
US20110092445A1 (en) * 2008-07-25 2011-04-21 Abbott Laboratories Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses
WO2010010469A2 (en) 2008-07-25 2010-01-28 Abbott Gmbh & Co. Kg Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
US8410243B2 (en) 2008-12-17 2013-04-02 The Governors Of The University Of Alberta Aromatic ether-containing fluorene monomers, processes for their preparation and polymerization thereof
JP2012513471A (ja) 2008-12-22 2012-06-14 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ アルツハイマー病および癌の治療のためのクマリン系化合物
EP2534490B1 (en) 2010-02-09 2015-12-16 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
SG183854A1 (en) 2010-03-03 2012-10-30 Univ British Columbia Oligomer-specific amyloid beta epitope and antibodies
WO2013071267A1 (en) 2011-11-10 2013-05-16 Cangene U.S., Incorporated Compositions and methods for treating alzheimer's disease
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Also Published As

Publication number Publication date
CN102858796B (zh) 2016-05-11
JP6494565B2 (ja) 2019-04-03
EP2542571A4 (en) 2013-07-31
EP2542571A1 (en) 2013-01-09
CA2791538A1 (en) 2011-09-09
CN102858796A (zh) 2013-01-02
IL221695B (en) 2019-01-31
US20160228522A1 (en) 2016-08-11
CL2012002438A1 (es) 2013-09-13
EP2542571B1 (en) 2016-05-25
EP3056510A1 (en) 2016-08-17
JP2016193914A (ja) 2016-11-17
BR112012022229A2 (pt) 2016-07-05
JP2013524774A (ja) 2013-06-20
CA2791538C (en) 2019-04-16
WO2011106885A1 (en) 2011-09-09
US9216217B2 (en) 2015-12-22
JP6190113B2 (ja) 2017-08-30
US20140314773A1 (en) 2014-10-23
NZ602548A (en) 2014-12-24
SG183854A1 (en) 2012-10-30
EP3056510B1 (en) 2018-10-03
MX2012010175A (es) 2012-11-23
RU2644335C2 (ru) 2018-02-08
KR101831459B1 (ko) 2018-04-04
ZA201206916B (en) 2014-03-26
KR20130045850A (ko) 2013-05-06
RU2012139043A (ru) 2014-04-10
AU2011223456A1 (en) 2012-10-18
US20130084283A1 (en) 2013-04-04
US9849165B2 (en) 2017-12-26
CO6640211A2 (es) 2013-03-22

Similar Documents

Publication Publication Date Title
MX341536B (es) Epitopo y anticuerpos beta amiloide de oligomero especifico.
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
TW200732348A (en) Monoclonal antibody
AU2018256498A1 (en) Antibodies to amyloid beta
EA201000809A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
TR201800669T4 (tr) Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇
MY164376A (en) Phosphospecific antibodies recognizing tau
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
MX341369B (es) Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
EP2403871A4 (en) SPECIFIC ANTIBODIES AND EPITOPES OF A PRION PROTEIN
UA107836C2 (uk) Метод лікування хвороби альцгеймера
JO3188B1 (ar) بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل
WO2012021475A3 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
EA201391097A1 (ru) СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА
WO2015043566A8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
MX2011012677A (es) Conjugados de albumina-peptido amiloide y usos de los mismos.
ME01075B (me) Antitijela
WO2013054110A3 (en) Compositions for binding to amyloid proteins
MX343873B (es) Ensayo de diagnostico de anticuerpo.
TH95385B (th) แอนติบอดีที่ได้รับการฮิวมาไนซ์

Legal Events

Date Code Title Description
FG Grant or registration